Expression of P-glycoprotein in hepatocellular carcinoma: A determinant of chemotherapy response

American Journal of Clinical Pathology

Volumn 113, Issue 3, 2000, Pages 355-363

  Ng, Irene O L ^a   Liu, Chi L ^b   Fan, Sheung T ^b   Ng, Matthew ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b NONE

Author keywords

Hepatocellular carcinoma; Liver; Multidrug resistance; P Glycoprotein

Indexed keywords

GLYCOPROTEIN P; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION;

EID: 0034100195     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/ac1m-4ty4-u0tn-en7t     Document Type: Article

References (32)

1. Deuchars KL, Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol. 1989;16:156-165.
2. Schinkel AH, Smit JJM, van Tellingen O, et al. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491-502.
3. Saltz L, Murphy B, Kemeny N, et al. A phase I trial of intrahepatic verapamil and doxorubicin: regional therapy to overcome multidrug resistance. Cancer. 1994;74:2757-2764.
4. Foxwell BMJ, Mackie A, Ling V, et al. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol. 1989;36: 543-546.
5. Callaghan R, Higgins CF. Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br J Cancer. 1995;71:294-299.
6. Chin KV, Ueda K, Pastan I, et al. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 1992;255:459-462.
7. Zastawny RL, Salvino R, Chen JM, et al. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene. 1995;8:1529-1535.
8. Hsu IC, Metcalf RA, Sun T, et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;550:427-428.
9. Isshiki K, Nakao A, Ito M, et al. P-glycoprotein expression in hepatocellular carcinoma. J Surg Oncol. 1993;52:21-25.
10. Itsubo M, Ishikawa T, Toda G, et al. Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer. 1994;73:298-303.
11. Soini Y, Virkajarvi N, Raunio H, et al. Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. J Clin Pathol. 1996;49:470-473.
12. Chou YY, Cheny AL, Hsu HC. Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation. J Gastroenterol Hepatol. 1997;12:569-575.
13. Takanishi K, Miyazaki M, Ohtsuka M, et al. Inverse relationship between P-glycoprotein expression and its proliferative activity in hepatocellular carcinoma. Oncology. 1997;54:231-257.
14. Ng IOL, Lai ECS, Fan ST, et al. Prognostic significance of pathologic features of hepatocellular carcinoma: a multivariate analysis of 278 patients. Cancer. 1995;76: 2443-2448.
15. Eggel H. Uber das primare Carcinoma der Leber. Beitr Pathol Anat Allg Pathol. 1910;30:506-604.
16. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 49800 necropsies. Cancer. 1954;7:462-503.
17. Ng WF, Sarangi F, Zastawny RL, et al. Identification of members of P-glycoprotein multigene family. Mol Cell Biol. 1989;9:1224-1232.
18. Georges E, Bradley G, Gariepy J, et al. Detection of P-glycoprotein isoforms by gene specific monoclonal antibodies. Proc Natl Acad Sci U S A. 1990;87:152-156.
19. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:201-214.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
21. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 1996;56:3010-3020.
22. Weinstein RS, Shriram MJ, Dominguez JM, et al. Relationship of the expression of the multidtug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res. 1991;51:2720-2726.
23. Linn SC, Honkoop AH, Hoekman K, et al. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer. 1996;74:63-68.
24. Monden N, Abe S, Sutoh I, et al. Prognostic significance of the expressions of metallothionein, glutathione-S-transferase-pi, and P-glycoprotein in curatively resected gastric cancer. Oncology. 1997;54:391-399.
25. Fujii H, Tangigawa N, Muraoka R, et al. Clinical significance of multidrug resistance and P-glycoprotein expression in patients with gastric carcinoma. J Surg Oncol. 1995;58:63-69.
26. Mizoguchi T, Yamada K, Furukawa T, et al. Expression of the MDR1 gene in human gastric and colorectal carcinomas. J Natl Cancer Inst. 1990;82:1679-1683.
27. Kanamaru H, Kakehi Y, Yoshida O, et al. MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of doxorubicin resistance by quinidine in tumor explants. J Natl Cancer Inst. 1989;81:844-849.
28. Chan HSL, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med. 1991;325:1608-1614.
29. Goldsmith M, Gudas JM, Schneider E, et al. Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J Biol Chem. 1995;270:1894-1898.
30. Linn SC, Honkoop AH, Hoekman K, et al. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer. 1996;74:63-68.
31. de Angelis P, Stokke T, Smedshammer L, et al. P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br J Cancer. 1995;72:307-311.
32. Schneider J, Rubio MP, Barbazan MJ, et al. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst. 1994;86:850-855.